Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT With [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
NCT02193672Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2014
- Primary completion
- Aug 2020
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of fluciclatide in cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Change in Tumor Uptake. Planned start Aug 2014; status: withdrawn.
02
Drugs
fluciclatide
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02193672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193672.